These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 19720812)

  • 21. Sitaxsentan therapy for pulmonary arterial hypertension.
    Barst RJ; Langleben D; Frost A; Horn EM; Oudiz R; Shapiro S; McLaughlin V; Hill N; Tapson VF; Robbins IM; Zwicke D; Duncan B; Dixon RA; Frumkin LR;
    Am J Respir Crit Care Med; 2004 Feb; 169(4):441-7. PubMed ID: 14630619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective or nonselective endothelin receptor blockade in pulmonary arterial hypertension.
    Wilkins MR
    Am J Respir Crit Care Med; 2004 Feb; 169(4):433-4. PubMed ID: 14766656
    [No Abstract]   [Full Text] [Related]  

  • 23. Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases.
    Humbert M; Simonneau G
    Nat Clin Pract Rheumatol; 2005 Dec; 1(2):93-101. PubMed ID: 16932638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sitaxsentan: an endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension.
    O'Callaghan DS; Gaine SP
    Int J Clin Pract; 2006 Apr; 60(4):475-81. PubMed ID: 16620363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual ET(A)/ET(B) vs. selective ET(A) endothelin receptor antagonism in patients with pulmonary hypertension.
    Opitz CF; Ewert R
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():1-9. PubMed ID: 16919004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade.
    Langleben D; Cacoub P
    Eur J Clin Invest; 2009 Jun; 39 Suppl 2():27-31. PubMed ID: 19335744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Endothelin-receptor antagonists in therapy of pulmonary arterial hypertension].
    Ghofrani HA
    Dtsch Med Wochenschr; 2009 Aug; 134 Suppl 5():S177-8. PubMed ID: 19718611
    [No Abstract]   [Full Text] [Related]  

  • 28. [Updated treatment of primary pulmonary hypertension -- the role of endothelin receptor antagonists].
    Callejas Rubio JL; Ortego Centeno N; Navarro Pelayo F; Vallejo Rodríguez I
    Farm Hosp; 2004; 28(4):294-5. PubMed ID: 15369441
    [No Abstract]   [Full Text] [Related]  

  • 29. Sitaxsentan in pulmonary arterial hypertension.
    Apostolopoulou SC; Rammos S
    Chest; 2003 May; 123(5):1772; author reply 1772-3. PubMed ID: 12740304
    [No Abstract]   [Full Text] [Related]  

  • 30. Endothelin receptor antagonists-induced hepatotoxicity.
    Macías Saint-Gerons D; de la Fuente Honrubia C; Montero D; Catalá-López F
    Intern Med J; 2013 May; 43(5):609-10. PubMed ID: 23668280
    [No Abstract]   [Full Text] [Related]  

  • 31. Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas.
    Mucke HA
    IDrugs; 2009 Jun; 12(6):366-75. PubMed ID: 19517317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of sitaxsentan sodium in patients with pulmonary arterial hypertension.
    Waxman AB
    Vasc Health Risk Manag; 2007; 3(1):151-7. PubMed ID: 17583185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of sitaxentan (Thelin®) toxicity in juvenile rats and regulatory interactions during the development of a European Medicines Agency pediatric investigation plan.
    Cross DM; Derzi M; Horsley E; Owen K; Stavros FL
    Regul Toxicol Pharmacol; 2012 Oct; 64(1):43-50. PubMed ID: 22683288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade.
    Zacà V; Metra M; Danesi R; Lombardi C; Verzura G; Dei Cas L
    Ther Adv Respir Dis; 2009 Feb; 3(1):11-4. PubMed ID: 19293198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug-related hepatotoxicity.
    McIntyre K
    N Engl J Med; 2006 May; 354(20):2191-3; author reply 2191-3. PubMed ID: 16710914
    [No Abstract]   [Full Text] [Related]  

  • 36. Pulmonary hypertension: basic concepts and practical management.
    Hoeper MM; Dinh-Xuan AT
    Eur Respir J; 2008 Feb; 31(2):236-7. PubMed ID: 18238945
    [No Abstract]   [Full Text] [Related]  

  • 37. CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers.
    Markert C; Burhenne J; Weiss J; Mikus G; Haefeli WE
    Clin Pharmacol Ther; 2014 Mar; 95(3):250-1. PubMed ID: 24048276
    [No Abstract]   [Full Text] [Related]  

  • 38. [Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists].
    Hoeper MM
    Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S308-10. PubMed ID: 17139593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response to "CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers".
    Markova SM; Schwartz JB; Kroetz DL
    Clin Pharmacol Ther; 2014 Mar; 95(3):252. PubMed ID: 24346422
    [No Abstract]   [Full Text] [Related]  

  • 40. Managing the risk of drug-induced liver injury.
    Watkins PB
    Clin Pharmacol Ther; 2013 Dec; 94(6):629-31. PubMed ID: 24241638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.